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Assembly of the CARD11/CARMA1-BCL10-MALT1 (CBM) signaling complex upon T
or B cell antigen receptor (TCR or BCR) engagement drives lymphocyte activation.
Recruitment of pre-assembled BCL10-MALT1 complexes to CARD11 fosters activation
of the MALT1 protease and canonical NF-κB signaling. Structural data and in vitro assays
have suggested that CARD11 acts as a seed that nucleates the assembly of BCL10
filaments, but the relevance of these findings for CBM complex assembly in cells remains
unresolved. To uncouple cellular CARD11 recruitment of BCL10 and BCL10 filament
assembly, we generated a BCL10-CARD11 fusion protein that links the C-terminus of
BCL10 to the N-terminus of CARD11. When stably expressed in CARD11 KO Jurkat T
cells, the BCL10-CARD11 fusion induced constitutive MALT1 activation. Furthermore, in
CARD11 KO BJAB B cells, BCL10-CARD11 promoted constitutive NF-κB activation to a
similar extent as CARD11 containing oncogenic driver mutations. Using structure-guided
destructive mutations in the CARD11-BCL10 (CARD11 R35A) or BCL10-BCL10 (BCL10
R42E) interfaces, we demonstrate that chronic activation by the BCL10-CARD11 fusion
protein was independent of the CARD11 CARD. However, activation strictly relied upon
the ability of the BCL10 CARD to form oligomers. Thus, by combining distinct CARD
mutations in the context of constitutively active BCL10-CARD11 fusion proteins, we
provide evidence that BCL10-MALT1 recruitment to CARD11 and BCL10 oligomerization
are interconnected processes, which bridge the CARD11 seed to downstream pathways
in lymphocytes.
Keywords: lymphocyte signaling, CARMA1–BCL10–MALT1 (CBM) signalosome complex, CARD11, NF- kappa B,
MALT1 paracaspase
INTRODUCTION
Assembly of the CARD11/CARMA1-BCL10-MALT1 (CBM) signalosome channels T and B
cell antigen-receptor (TCR/BCR) ligation to MALT1 protease activation and canonical NF-κB
signaling (1, 2). CARD11 phosphorylation, primarily in the central linker region, following
antigenic stimulation induces conformational changes that expose the N-terminal CARD (Caspase
Recruitment Domain) to recruit pre-assembled BCL10-MALT1 complexes (3, 4). Oncogenic
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CARD11 variants have been identified mainly in the coiled-
coil domain, and these activating mutations promote chronic
CBM assembly and NF-κB-driven survival in diffuse large B cell
lymphomas (DLBCL) in the absence of antigenic stimulation
(5, 6).
It is well established that BCL10 associates with the CARD-
containing scaffold protein CARD11 through heterotypic
CARD-CARD interactions (7, 8). Overexpression studies
indicate that BCL10, via its N-terminal CARD, forms filament-
like clusters in cells, which are required for proper activation
of canonical NF-κB signaling (9). Aggregation of BCL10 in
foci was also observed following TCR ligation in T cells (10).
More recent in vitro structural studies, combined with molecular
modeling, have demonstrated that the CARD of CARD11 can
function as a seed to nucleate the assembly of BCL10 CARD
filaments (11–13). In vitro BCL10 filaments can also form in
the absence of CARD11, but CARD11 decreases the lag period
of BCL10 polymerization and thus appears to function as an
initiator of the process (11). Impaired MALT1 activity and
NF-κB signaling upon overexpression of CARD11 or BCL10
mutants, targeting either the heterotypic CARD11-BCL10 or
the homotypic BCL10-BCL10 CARD interfaces, highlights the
importance of the different CARD surfaces (12, 13). These
experiments, however, did not address the contribution of
the different interfaces to antigenic activation when expressed
at endogenous levels. We have demonstrated that BCL10
oligomerization is also required for its recruitment to CARD11,
indicating that both processes are highly interconnected (14).
Thus, the cellular relevance of the CARD11 seeding function for
BCL10 filament formation, as well as, the order of events after
antigenic stimulation, have not been resolved.
Here, we used CRISPR/Cas9 technology to generate CARD11
and BCL10 KO T and B cell lines and stable lentiviral
reconstitution, to investigate the cellular necessity of the
CARD11 seed and BCL10 filaments in a clean genetic setup under
physiological conditions. As noted earlier, we have been unable
to definitively determine whether CARD11 nucleates BCL10
filaments or, if BCL10 filament formation happens prior to, or at
the same time as CARD11 recruitment in stimulated T cells using
missense mutations in the putative CARD11-BCL10 or BCL10-
BCL10 interfaces alone (14). Thus, we uncoupled these processes
by fusing BCL10 to CARD11 to bypass inducible recruitment and
thereby were able to investigate the cellular necessity of CARD11
seeding and BCL10 oligomerization.
RESULTS
BCL10 Recruitment to CARD11 and BCL10
Filament Assembly Are Interconnected
Processes
In order to predict mutations that would selectively interfere
with CARD11 seed function or BCL10 self-assembly, we used
structural modeling to fit the CARD11 seed onto the structure
of BCL10 CARD filaments (Figure 1A). Therefore, the CARD11
CARD domain crystal structure was superimposed on to three
BCL10 CARD domains at the bottom of the BCL10 filament
cryo EM structure [Figure 1A; (13, 14)]. Since the structure
of the CARD11-BCL10 interface has not been determined,
the CARD11 BCL10 CARD/CARD interaction was modeled in
consideration of the surface charge complementarity analysis of
the BCL10-MALT1 filament cryo-EM structure and the crystal
structure of the CARD11 (Supplementary Figures 1A–C). As
noted earlier, distinct interfaces between the CARDs are
required to mediate heterotypic CARD11-BCL10 interactions
or homotypic BCL10-BCL10 interactions (12, 13). On the
CARD11 side, R35 serves as a critical contact point to multiple
residues in BCL10 including E53 and mediates recruitment
of BCL10 to CARD11 [Figure 1B; (12)]. On BCL10, R42
contributes to the association at the BCL10-BCL10 interface
I that controls BCL10 oligomerization (Figures 1C,D). The
structure reveals that R42 is not predicted to confer CARD11-
BCL10 interaction (11, 13, 14). In vitro, the BCL10 CARD
mutation R42E prevents oligomerization of the BCL10-MALT1
complex (14). We expressed BCL10 WT and R42E in adherent
U2OS cells to monitor formation of cellular clusters. Indeed,
whereas overexpressed BCL10 WT forms cytosolic aggregates
in U2OS cells, BCL10 R42E fails to cluster, indicating that
oligomerization and filament formation is prevented by the
mutation (Figure 1E). We performed co-immunoprecipitation
(IP) of HA-BCL10 WT, together with Flag-BCL10 WT or R42E
in HEK293 cells (Figure 1F). Despite the higher expression
of BCL10 R42E, only Flag-BCL10 WT co-precipitated with
HA-BCL10, validating that the mutation abolishes BCL10
self-association.
To rigorously test the function of CARD11 as a molecular
seed and BCL10 as a filament forming CARD11 adaptor
in B and T cells, we generated CARD11 and BCL10 KO
Jurkat T cells, as well as CARD11 KO BJAB B cells, by
CRISPR/Cas9 technology (Supplementary Figure 2). CARD11
KO Jurkat T and BJAB B cells were generated using sgRNA
targeting Exon3, which induces double stranded breaks and
frame shift mutations due to non-homologous end-joining
(NHEJ) repair (Supplementary Figure 2A). An exon1-intron1
deletion strategy using two sgRNA was employed to knockout
BCL10 from Jurkat T cells (Supplementary Figure 2B). Using
these approaches, we obtained several clones that displayed loss
of CARD11 or BCL10 expression as determined by Western
Blot analysis (Supplementary Figures 2C–E). Destructive frame
shift mutations in CARD11 or deletions of BCL10 in both
alleles were confirmed by sequencing of the genomic loci in
the respective KO cell clones (data not shown). We used
PMA/Ionomycin (P/I) stimulation, which bypasses upstream
TCR or BCR signaling by directly activating PKCθ or PKCβ in
T and B cells and increasing cytosolic calcium levels. In line
with the key role of the CBM complex, CARD11 or BCL10
deficiency abolished P/I-induced NF-κB signaling in Jurkat T or
BJAB B cells as evident from lack of IκBα degradation and NF-
κB DNA binding (Supplementary Figures 2C–E). In contrast,
CBM-independent, TNFα-driven NF-κB signaling as well as ERK
activation were not affected by the absence of CARD11 in Jurkat
T cells, demonstrating that loss of the CBM complex selectively
affects antigenic signaling. Thus, the absence of CARD11 or
BCL10 in Jurkat and BJAB cells faithfully mirrors the signaling
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FIGURE 1 | CARD-CARD interfaces in the CARD11-BCL10 structure. (A) Model of the CARD11-BCL10 filament structure. The oligomeric CARD11 seed (PDB
4LWD, orange) induces BCL10 (PDB 6GK2, blue) filament assembly through the heterotypic CARD11-BCL10 interface. (B) Close-up view of CARD11 R35 (magenta)
contacting BCL10 E53 in the modeled CARD11-BCL10 interface. (C,D) Close-up view of the BCL10-BCL10 interface I. Residues involved in homotypic CARD-CARD
association as observed in the cryo-EM structure (EMD-0013, PDB 6GK2) (14) are shown as sticks. The mutated residue R42 is highlighted in green. (E) Cellular
distribution of BCL10 in U2OS cells was determined after transfection of BCL10-FS or BCL10 R42E-FS and aggregate clustering was detected by indirect confocal
immunofluorescence microscopy. Scale bars depict 10µm. Average number of aggregated foci was quantified by blinded counting >30 cells per condition (mean ±
s.e.m.; **p ≤ 0.01). (F) HEK 293 cells were transfected with Flag- and HA-tagged BCL10 constructs as indicated, and self-association of HA-BCL10 WT to
Flag-BCL10 WT or R42E mutant was determined after Flag-IP.
defects observed in primary lymphocytes from CARD11−/− or
BCL10−/− mice (15–17).
We then performed rescue experiments in Jurkat KO T cells
to study the molecular functions of the CARD11 and BCL10
CARDs, by introducing missense mutations (CARD11 R35A and
BCL10 R42E) that are both predicted to selectively interfere
with heterotypic CARD11-BCL10 and homotypic BCL10-BCL10
interactions, respectively [Figures 1, 2A; (12, 14)]. Jurkat
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FIGURE 2 | Effects of destructive heterotypic and homotypic CARD-CARD interface mutants. (A) Schematic presentation of CARD11 and BCL10 WT proteins and
the respective CARD mutants R35A and R42E. (B) CARD11 KO Jurkat T cells were reconstituted with CARD11 WT or R35A. Cells were stimulated with P/I (30min)
and effects on NF-κB signaling were determined by following IκBα degradation by WB and NF-κB activation by EMSA. (C) CARD11 KO Jurkat T cells were
reconstituted as in (B), stimulated with P/I (30min), and MALT1 protease activity was determined via MALT1-ABP PD assay and assessment of substrate cleavage
(CYLD and HOIL1) by WB. (D) BCL10 KO Jurkat T cells were reconstituted with BCL10 or BCL10 R42E. Cells were stimulated with P/I (30min) and NF-κB signaling
was analyzed as in (B). MALT1 protease activity was determined by CYLD substrate cleavage by WB. (E) Recruitment of BCL10 or BCL10 R42E to CARD11 after P/I
stimulation (15min) in Jurkat T cells was monitored by ST-PD and subsequent WB. The asterisks indicate an unspecific band in the BCL10WB.
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CARD11 or BCL10 KO T cells were reconstituted by lentiviral
transduction and comparable infection rates for epitope-tagged
(FS: Flag-StrepTag2) CARD11 and BCL10 constructs were
obtained, as determined by co-expression of the surface marker
1CD2 (Supplementary Figures 3A,B). Equivalent expression
of WT and mutant CARD11 or BCL10 proteins at close
to endogenous levels was confirmed by Western Blotting
(Supplementary Figures 3A,B). Functionally, lack of CARD11-
dependent NF-κB activation after P/I stimulation in CARD11KO
cells was rescued upon reconstitution with CARD11WT, but not
with the CARD11 R35A mutant (Figure 2B). We also assessed
activation of the MALT1 protease by substrate cleavage (CYLD
and HOIL-1) (18) and labeling of active MALT1 by a biotinylated
MALT1 activity-based probe (ABP) followed by biotin pull-
down (PD) to capture active MALT1 [Figure 2C; (19)]. Again,
CARD11WT, but not R35A, could rescue P/I stimulated MALT1
protease activation in Jurkat T cells, revealing that this mutation
abolishes all CARD11 downstream function. On the side of
BCL10, we confirmed that rescue of BCL10 WT, but not
BCL10 R42E, was able to trigger MALT1 activation and mediate
NF-κB downstream signaling in response to P/I stimulation
[Figure 2D; (14)]. Since the structural analyses suggested that
BCL10 R42E would selectively disrupt the BCL10-BCL10 but
not the CARD11-BCL10 interface (13), we asked if BCL10 R42E
could still be recruited to CARD11 upon stimulation. However,
no stimulation-dependent binding to CARD11 was detected with
BCL10 R42E mutant [Figure 2E; (14)]. The data demonstrate
that CARD11 recruitment and BCL10 filament formation are
interconnected processes. Thus, destructive mutations in the
CARD11-BCL10 or BCL10-BCL10 interfaces alone are unable
to resolve whether CARD11 acts as a seed to induce BCL10
oligomerization or if an initial BCL10 filament assembly may be
required for the recruitment of BCL10-MALT1 to CARD11.
BCL10-CARD11 Fusion Drives Constitutive
MALT1 Activation Through BCL10
Oligomerization in Jurkat T Cells
To test the necessity for BCL10 self-association downstream
of CARD11, we designed a system that bypasses inducible
CARD11-BCL10 association. For this we cloned chimeric
proteins that covalently fuse BCL10 through its C-terminus to the
N-terminus of CARD11 (Figure 3A). We lentivirally transduced
CARD11 KO Jurkat T cells with the SF-tagged BCL10-CARD11
construct (herein referred to as B10-C11 fusion) (Figure 3B). We
detected a faint but distinct band corresponding to the expected
size of the B10-C11 fusion using αBCL10 and αCARD11
antibodies (Figure 3C). Notably, expression of the B10-C11
protein triggered constitutive cleavage of CYLD and A20, as
well as a reduction in endogenous BCL10, which are all MALT1
substrates (18). However, the BCL10-CARD11 fusion itself,
which contains a MALT1 cleavage site at R228 in the BCL10
moiety (20), was also prone to processing, giving rise to a
fragment the size of endogenous CARD11 (Figure 3C). Thus, the
data clearly indicate that fusion of BCL10 to CARD11 is sufficient
to induce MALT1 activation.
To avoid the indirect reconstitution of CARD11 from the
cleaved B10-C11 fusion, we designed all further BCL10-CARD11
fusion constructs so that they contained the MALT1 cleavage
resistant BCL10 R228A mutation (Figure 3A). The fusion
constructs include the destructive mutations R42E in the BCL10
CARD, and R35A in the CARD11 CARD, both alone and in
combination. All B10-C11 fusion constructs were transduced
into CARD11 KO Jurkat T cells, yielding equivalent infection
efficiencies as judged by 1CD2 expression (Figure 3D). The
chimeric proteins were expressed below the level of endogenous
CARD11 and moreover, the fusions containing a functional
WT BCL10 CARD were consistently expressed at lower levels
compared to the BCL10 mutants R42E that prevent BCL10
oligomerization (Figure 3E). StrepTactin pull-downs (ST-PD)
demonstrated that the BCL10-CARD11 fusion proteins retained
the ability to bind endogenous MALT1, excluding that the
fusion or point mutations in the CARDs interfere with MALT1
recruitment (Figure 3E).
Using biotin-PD after incubation with bio-MALT1-ABP, we
tested MALT1 protease activity in extracts of untreated and
P/I stimulated Jurkat T cells (Figure 3F). Expression of B10
R228A-C11, containing two functional CARDs, as well as the
B10 R228A-C11 R35A fusion, with an inactivation only in the
CARD11 CARD, induced strong MALT1 protease activity that
was equivalent to the activation obtained in Jurkat T cells after
P/I stimulation. Despite robust MALT1 activation, the R228A
exchange in BCL10 prevented cleavage of the fusion constructs
and thus the appearance of CARD11 (Figure 3E). Constitutive
MALT1 activation was abrogated in the B10-C11 fusion proteins
carrying the oligomerization-defective BCL10 R42E mutation,
providing evidence that constitutive MALT1 activation is driven
through oligomerization of endogenous BCL10 via the BCL10
CARD (Figure 3F). Interestingly, MALT1 activity was further
enhanced after stimulation of B10 R228A-C11 expressing cells
and this strictly relied on the CARD11 CARD, because the
R35A mutation prevented stimulation-dependent induction. In
line, even though the B10 R42E/R228A-C11 fusion containing
an intact CARD11 CARD was unable to induce constitutive
MALT1 activation, it was still able to mediate MALT1 activation
in P/I-stimulated Jurkat T cells. Thus, stimulation dependent
activation seems to rely on the recruitment of endogenous BCL10
to the CARD11 CARD in the context of the BCL10-CARD11
fusion protein. In fact, the B10 R42E/R228A-C11 fusion acted
completely independently of the BCL10 CARD and exactly
mirrored the rescue observed when using CARD11 WT (see
Figures 2B,C). In agreement with these data, the triple mutant
B10 R42E/R228A-C11 R35A neither promoted constitutive, nor
rescued, stimulus-dependent MALT1 activation.
To confirm these findings on the level of MALT1 substrates,
we assessed cleavage of CYLD, HOIL1 and A20 in B10-C11
expressing cells (Figure 3G). Cleavage of the three substrates was
observed in Jurkat T cells expressing the fusions with an intact
BCL10 CARD (B10 R228A-C11 and B10 R228A-C11 R35A),
confirming that constitutive MALT1 protease activity relies on
BCL10 oligomerization. The intact CARD11 CARD in B10 R42E
R228A-C11 still conferred inducible substrate cleavage, which
was especially evident for HOIL1 that is also most strongly
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FIGURE 3 | A chimeric BCL10-CARD11 fusion protein induces constitutive MALT1 protease activity in Jurkat T cells through the BCL10 oligomerization interface.
(A) Schematic representation of BCL10-CARD11 (B10-C11) fusion proteins with the respective CARD mutants. (B) Transduction efficiency of CARD11 KO Jurkat T
cells with BCL10-CARD11 (B10-C11) was analyzed by FACS using the surface marker 1CD2. (C) Protein expression of B10-C11 fusion construct and cleavage of
MALT1 substrates compared to mock and parental Jurkat T cells was analyzed by WB. (D) Transduction efficiency of CARD11 KO Jurkat T cells with different B10
R228A-C11 fusion constructs as in (B). (E) Expression of the different B10 R228A-C11 fusion proteins compared to mock and parental Jurkat T cells was analyzed
by WB and binding to MALT1 assessed by Strep-PD. (F) CARD11 KO Jurkat T cells were reconstituted with B10 R228A-C11 fusion proteins as indicated. Active
MALT1 prior or after P/I stimulation (30min) was detected in the extracts with biotin-labeled MALT1-ABP and MALT1-ABP PD followed by WB. (G) CARD11 KO
Jurkat T cells were reconstituted and treated as in (F) and cleavage of MALT1 substrates (CYLD, HOIL1, A20) was detected by WB.
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cleaved after P/I stimulation of Jurkat T cells. Again, destruction
of both CARDs in B10 R42E/R228A-C11 R35A led to complete
loss of constitutive and inducible MALT1 activation. Thus,
covalent attachment of BCL10 to the N-terminus of CARD11
is sufficient to induce MALT1 protease activation, which still
relies on the oligomerization interface of the fused BCL10moiety.
These data support the concept that, in cells, CARD11 acts as a
seed to induce BCL10 filament assembly.
Transient Expression of BCL10-CARD11
Induces NF-κB Activation in Jurkat T Cells
Interestingly, when we tested activation of NF-κB by B10-C11
fusion constructs in CARD11 or BCL10 KO Jurkat T cells we
noticed a severely blunted response in EMSA (Figure 4A). There
was a weak induction of constitutive NF-κB DNA binding in
B10 R228A-C11, but IκBα degradation and NF-κB activation was
only mildly triggered after P/I stimulation, revealing that stable
expression of the active BCL10-CARD11 fusion may promote
a stage of unresponsiveness in Jurkat T cells. Again, missense
mutations in both CARDs completely prevented constitutive,
as well as, inducible NF-κB activation in the context of the
B10-C11 fusion protein. We switched to a transient transfection
system and NF-κB reporter assays to investigate if BCL10-
CARD11 fusion proteins can activate NF-κB. Indeed, NF-κB was
strongly induced by the expression of B10 R228A-C11 fusion
activated in parental Jurkat T cells or CARD11 KO Jurkat T
cells (Figures 4B,C). However, in line with the EMSA results
overall NF-κB activation was strongly diminished when the
reporter assay was performed in CARD11 KO Jurkat T cells
that stably express the B10-C11 fusion constructs (Figure 4C).
Further, the oligomerization-deficient BCL10 R42E mutant
severely reducedNF-κB activation by the BCL10-CARD11 fusion
protein. Again, also in transient transfection we observed that
BCL10-CARD11 was expressed at much lower levels compared
to the B10 R42E/R228A-C11 protein, suggesting that there is
a counter-selection against the expression of the active BCL10-
CARD11 fusion. NF-κB induction of BCL10-CARD11 fusion
protein was comparable to the induction achieved by oncogenic
CARD11 L225LI or CARD11 1linker, especially taking into
account the much weaker expression of the fusion protein
[Figure 4C; (6, 21)]. To check if the generated BCL10-CARD11
fusion construct does not trigger unphysiological NF-κB that
bypasses the necessity of known regulators, we determined
the requirement for MALT1 and for TRAF6 recruitment to
MALT1 (Figure 4D). NF-κB activation in response to antigenic
stimulation is abolished MALT1 KO Jurkat T cells and signaling
can be rescued by transduction of MALT1A or MALT1B, but
not the respective MALT1 TRAF6 binding mutants (22). As
expected, expression of B10 R228A-C11 or CARD11 1linker
was unable to activate NF-κB in MALT1 KO Jurkat T cell
(Figure 4D). While NF-κB activity was recovered by viral
complementation with MALT1B WT, the MALT1B E795A
mutant that destroys the only functional TRAF6 binding motif
on MALT1B failed to rescue reporter gene expression, proving
that MALT1 and TRAF6 are utilized by the BCL10-CARD11
fusion protein to activate NF-κB [Figure 4D; (22–24)]. Thus,
while transient expression of the BCL10-CARD11 fusion protein
promotes NF-κB activation, NF-κB responses are dampened in
Jurkat T cells after stable expression of the fusion proteins.
To corroborate whether the BCL10-CARD11 fusion protein
can also compensate for BCL10 deficiency, we transduced
BCL10 KO Jurkat T cells with the B10 R228A-C11 fusion
protein (Supplementary Figure 4A). Indeed, fusion of BCL10
to CARD11 was able to trigger constitutive CYLD, A20, and
HOIL1 cleavage and thus to drive MALT1 protease activation
in BCL10 deficient cells (Supplementary Figure 4B). Again,
mutation of BCL10 and CARD11 CARD (B10 R42E/R228A-C11
R35A) prevented constitutive and inducible MALT1 activation,
underscoring that dimerization/oligomerization of the fusion
proteins is required. Similar to the situation in CARD11 KO
cells, NF-κB activation was blunted upon stable expression of B10
R228A-C11 in BCL10 KO Jurkat T cells.
BCL10-CARD11 Fusion Acts Like
Oncogenic CARD11 in BJAB B Cells
To better explore the impact of stable BCL10-CARD11 fusion on
NF-κB activation, we switched to GCB DLBCL derived BJAB B
cells, which under basal conditions are devoid of NF-κB activity,
but overexpression of oncogenic CARD11 mutants induces
strong chronic NF-κB activity (5, 6, 25). We generated CARD11
KO BJAB B cells (Supplementary Figure 2D) and confirmed
that the phenotype of the BJAB KO cells was caused by loss of
CARD11. For this we reconstituted the cells with CARD11 WT,
or the oncogenic CARD11 coiled-coil (CC) mutant L225LI that
induces robust NF-κB and proliferation upon overexpression in
B cells [Figure 5A; (25, 26)]. After viral transduction, BJAB B
cells expressed CARD11WT and CARD11 L225LI slightly above
endogenous levels (Figures 5B,C). CARD11 WT was able to
recover P/I-inducible NF-κB andMALT1 protease activation, but
was not associated with constitutive activation (Figures 5D,E).
In contrast, transduction of CARD11 L225LI was sufficient to
promote constitutive NF-κB activation, as well as cleavage of the
MALT1 substrates BCL10, CYLD, A20 and HOIL1. This effect
was not further augmented by P/I stimulation (Figures 5D,E).
Thus, CARD11 KO BJAB B cells represent a valid system to
elucidate the impact of BCL10-CARD11 fusions on NF-κB
signaling.
Next, we expressed B10 R228A-C11 and B10 R42E/R228A-
C11 in CARD11 KO BJAB B cells (Figure 6A). In addition, we
sought to determine whether an oncogenic mutant of CARD11
also relies on BCL10 oligomerization. We have previously shown
that the activating potential of CARD11 L225LI is abolished
by the R35A mutation (25). Therefore, we expressed the B10-
C11 L225LI fusion constructs in the context of the CARD
destructive R35Amutation so that they should rely on the BCL10
CARD (B10 R228A-C11 R35A/L225LI and B10 R42E/R228A-
C11 R35A/L225LI) (Figure 6A). All constructs were transduced
in BJAB B cells to a similar extent, as determined by the surface
marker1CD2, but protein expression was far below endogenous
CARD11 (Figures 6B,C). As observed in Jurkat T cells, B10
R228A-C11 constructs containing an intact BCL10 CARD were
expressed at much lower levels and the variant containing
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FIGURE 4 | Transient expression of chimeric BCL10-CARD11 fusion protein in Jurkat T cells triggers NF-κB activation. (A) NF-κB signaling was analyzed in CARD11
KO Jurkat T cells stably reconstituted with different B10 R228A-C11 fusion proteins as indicated. IκBα degradation was determined by WB and NF-κB activation was
analyzed by EMSA. (B) B10-C11 fusion constructs were transiently expressed in Jurkat T cells together with a dual NF-κB reporter, and NF-κB induction was
assessed by a dual luciferase reporter assay. Protein levels were analyzed by WB. Results are displayed relative to mock-transfected cells (mean ± s.e.m.; n = 5).
(C) Jurkat CARD11 KO cells were transiently or stably reconstituted with B10-C11 fusion or CARD11 constructs and NF-κB activity determined as in (B). Expression
of the fusion constructs was verified by WB (mean ± s.e.m.; n = 3). (D) Transient expression of B10 R228A-C11 and CARD11 1linker in Jurkat MALT1 KO cells
stably reconstituted with mock, MALT1 IsoB wildtype and the TRAF6 binding motif mutant E795A, respectively. NF-κB activity was determined as described in (B) and
protein levels visualized on WB (mean ± s.e.m.; n = 3). **p ≤ 0.01, ***p ≤ 0.001.
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FIGURE 5 | Rescue of CARD11 KO BJAB B cells by CARD11 WT and oncogenic CARD11 L225LI. (A) Schematic representation of CARD11 and CARD11 L225LI
proteins. (B) Transduction of CARD11 KO BJAB B cells with CARD11 or CARD11 L225LI expressing lentiviruses was analyzed by the surface marker 1CD2 using
FACS. (C) CARD11 and CARD11 L225LI protein expression, compared to parental BJAB B cells, was determined by WB. (D) CARD11 KO BJAB B cells after
reconstitution with CARD11 WT or oncogenic CARD11 L225LI were analyzed for NF-κB activation after P/I stimulation (30min) by EMSA. (E) MALT1 protease activity
upon P/I stimulation (30min) in CARD11 KO BJAB B cells reconstituted with CARD11 or CARD11 L225LI was determined by CYLD, A20, and HOIL1 cleavage on WB.
the oncogenic mutation (B10 R228A-C11 R35A/L225LI) was
hardly detectable (Figure 6C lane 5). However, just like in
Jurkat T cells, the B10 R228A-C11 fusion induced strong
constitutive MALT1 activation, as evident from CYLD, HOIL1
and A20 cleavage, which strictly relied upon the BCL10 CARD
interface (Figure 6D). Furthermore, the BCL10-CARD11 fusion
combined with the oncogenic mutation L225LI (B10 R228A-
C11 R35A/L225LI) induced MALT1 activation, despite its very
low expression in the BJAB B cells. Again, constitutive MALT1
activation in the oncogenic BCL10-CARD11 fusion required
BCL10 oligomerization, but was independent of the CARD11
CARD (Figure 6D).
Further, the fusion of BCL10 to CARD11 was sufficient
to induce constitutive NF-κB activation in the BJAB B cells
that was not further enhanced by P/I treatment (Figure 6E).
Constitutive NF-κB activation was equivalent to that induced
by the oncogenic CARD11 variant L225LI (Figure 5D). Despite
its very weak expression, the oncogenic fusion construct B10
R228A-C11 R35A/L225LI also induced strong NF-κB activation,
suggesting that the combination of fusion with the oncogenic
mutant can generate a super-activator that is capable of further
boosting CBM signaling. The weak expression of the B10 R228A-
C11 R35A/L225LI suggests that there is a strong counter-
selection against expression of the hyper-active fusion protein.
Again, the constitutive activation observed with expression of
the fusion constructs was solely driven by the BCL10 filament
interface and was severely reduced in cells expressing the
double CARD mutant B10 R42E/R228A-C11 R35A/L225LI.
Finally, we confirmed that the fusion constructs also induce
NF-κB-dependent gene expression by demonstrating that the
prototype NF-κB target gene, NFKBIA/IκBα, is upregulated to
a similar degree in the BJAB B cells expressing either CARD11
L225LI or the activating B10-C11 fusion constructs (Figure 6F).
Thus, with respect to signaling, the fusion of BCL10 to CARD11
acts like an oncogenic CARD11 variant in B cells, through
oligomerization of the BCL10 CARD interface.
DISCUSSION
BCL10 CARD filaments are formed in vitro and the molecular
architecture of these clusters has been elucidated by cryo-electron
microscopy (11, 13, 14). Although it is possible for BCL10
filaments to form in the absence of CARD11, the CARD of
CARD11 appears to promote the initiation of BCL10 clustering
in a cell free system. Further, CARD11 is solely located at the
tip of the BCL10 filaments, lending support to the hypothesis
that CARD11 functions as the molecular seed for BCL10
oligomerization (11, 13). Structure-guided missense mutations
in the CARDs of CARD11 or BCL10 have been generated to
show that destruction of putatively homotypic (BCL10-BCL10)
or heterotypic (CARD11-BCL10) CARD-CARD interactions
impedes NF-κB signaling and MALT1 protease activation after
overexpression in cells (13, 14).
The functional impact of missense mutations in the CARDs
of CARD11 or BCL10 on stimulus-dependent CBM complex
signaling has not been thoroughly investigated. By reconstituting
CARD11 or BCL10 KO Jurkat T cells, we assessed how
destruction of putative CARD11-BCL10 or BCL10-BCL10
interfaces would affect signaling when expressed at endogenous
levels. As expected, the CARD11 mutation R35A prevented T
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FIGURE 6 | Constitutive NF-κB and MALT1 activation by an oncogenic BCL10-CARD11 fusion protein relies on the BCL10 CARD interface in BJAB B cells.
(A) Schematic representation of BCL10-CARD11 (B10-C11) fusion proteins containing CARD and oncogenic coiled-coil (CC) mutations. (B) Transduction of CARD11
KO BJAB B cells with B10 R228A-C11 fusion constructs, as depicted, was analyzed for the 1CD2 surface marker by FACS. (C) Protein expression of the fusion
constructs compared to parental BJAB B cells was determined by WB. (D) CARD11 KO BJAB B cells were reconstituted with B10 R228A-C11 fusion proteins as
indicated. Constitutive and P/I-inducible (30min) MALT1 activity was detected by CYLD, A20, and HOIL1 cleavage. (E) CARD11 KO BJAB B cells were reconstituted
as in (D) and NF-κB activity was analyzed by EMSA. (F) Expression of the NF-κB target gene NFKBIA/IκBα in CARD11 and B10 R228A-C11 expressing BJAB B cells
was determined by quantitative RT-PCR. All values were normalized to the housekeeping gene RPII and related to CARD11 (mean ± s.e.m, p-values as indicated).
cell stimulation due to its inability to recruit BCL10 (12, 25).
In addition, the BCL10-BCL10 interface mutant R42E could
not rescue NF-κB signaling in BCL10 KO cells, which confirms
the critical function of BCL10-BCL10 interface I for filament
assembly and signaling (13). Recently, we have been able to
solve the architecture of the BCL10-MALT1 filaments using
cryo-EM (14). Surprisingly, we found that different mutations
in the interface I that lead to loss of BCL10 filament assembly
also abolished CARD11 recruitment of BCL10 and thus CBM
complex formation (14). Thus, our results question if CARD11
acts as the seed to nucleate BCL10 filaments, or whether an
initial oligomerization of BCL10 is required for the recruitment
to CARD11 in cells. Alternatively, our data would also be in
line with a model in which CARD11-BCL10 association, but
not BCL10 oligomerization, is critical to promote signaling in
lymphocytes, and that filament formation is only observed with
recombinant BCL10 or after high overexpression of BCL10.
To clarify the necessity of the CARD11 seed and BCL10
filaments for T and B cell activation, we fused BCL10 to
CARD11 to bypass the initial step of heterotypic CARD-CARD
interaction between CARD11 and BCL10. Even though this is
an artificial system, it provided the first opportunity to examine
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the contribution of the individual CARDs in CARD11 and
BCL10. Remarkably, stable expression of the BCL10-CARD11
fusion protein promoted strong and chronic MALT1 protease
activity in Jurkat T cells. While NF-κB activation was blunted in
transduced Jurkat T cells, the transient transfection of BCL10-
CARD11 activated NF-κB to a similar extent as an oncogenic
CARD11 variant or CARD11 lacking the negative regulatory
linker region (CARD11 1linker) (5, 6, 21). Interestingly, the
BCL10-CARD11 fusion is not prone to auto-inhibition by the
CARD11 linker, which acts as an inhibitory domain (27). In the
fusion protein the BCL10 CARD is exposed and most likely not
accessible for the CARD11 linker, especially when considering
that an additional CARD cannot be bound by the linker in a
1:1 stoichiometry. Moreover, CARD11 and BCL10 CARDs are
homologous, but also quite distinct and the BCL10 CARD may
complex with the CARD11 linker, which would be critical for
auto-inhibition (5, 27). Despite the disrupted auto-inhibition, the
BCL10-CARD11 fusion protein signals to NF-κB via MALT1 and
the TRAF6 bindingmotif onMALT1, underscoring that it utilizes
the same mechanisms as a physiological CBM complex following
T cell activation.
Despite the structural elucidation of BCL10-MALT1 filaments
in vitro, the nature and relevance of cellular BCL10 oligomeric
structures has not been fully resolved. BCL10 tends to aggregate
via its CARD into oligomeric clusters and extended filaments
after overexpression in cells (7, 9). Endogenous BCL10 forms
oligomeric structures in antigen-stimulated T cells termed
POLKADOTS (“punctuated and oligomeric killing or activating
domains transducing signals”), which are cellular foci that
serve as functional platforms for recruiting NF-κB signaling
mediators following TCR stimulation (10, 28). Size exclusion
chromatography demonstrated that in stimulated Jurkat T
cells or ABC DLBCL tumor cells CARMA1, BCL10, and
MALT1 assemble into higher order complexes with an apparent
molecular weight >1 Mio. Da and the purified CBM complex
displayed a filament-like structure in electron microscopy (13,
29). However, by increasing the concentration of BCL10 during
the process of CBM purification, BCL10 filament formation may
be initiated in vitro rather than taking place in living cells. Thus,
there is good evidence that BCL10 can cluster via the CARD in
cells, but the existence of large helical BCL10 filaments under
physiological conditions in antigen-stimulated T or B cells has
not been formally demonstrated. Since it may be difficult to
imagine that the BCL10-CARD11 fusion itself can form long
filaments in the absence of endogenous BCL10, activation by the
fusion in BCL10 KO cells may indicate that BCL10-dependent
dimerization or short oligomerization may be sufficient for
lymphocyte activation. As for endogenous CARD11-associated
BCL10, monitoring of BCL10 filament formation in the context
of BCL10-CARD11 fusion is difficult with current methods,
because of low expression levels. High resolution imaging
techniques will be necessary to solve the extent of oligomerization
and the cellular architecture of the BCL10 clusters. However,
so far imaging in lymphocytes has been hampered by the
unavailability of high quality antibodies as well as the small
and round-shaped T and B cells that contain very little
cytoplasm.
An important question that remains is the in vivo necessity
for the formation of large, extended BCL10 filaments for signal
propagation. The lack of NF-κB and MALT1 activation in
BCL10 R42E in the context of the BCL10-CARD11 fusion
reflects the need for BCL10 dimerization/oligomerization, but
does not prove the requirement for higher order filaments.
Alternatively, BCL10-MALT1 recruitment to CARD11 and
BCL10 dimerization or short oligomers may be sufficient to
facilitate cellular processes such as ubiquitination of CBM
complex components. A number of ubiquitin ligases [e.g.,
TRAF6, LUBAC (linear ubiquitin chain assembly complex) and
cIAP2] are recruited to the CBM complex and conjugation of
mono-ubiquitin or poly-ubiquitin chains of different topology on
all subunits has been implicated in triggering MALT1 activation
and/or downstream signaling (1, 2). The complexity of ubiquitin-
dependent regulation is exemplified by BCL10. K48-, K63-, or
M1-linked ubiquitin chains are primarily conjugated on K17,
K31, and/or K63 in the BCL10 CARD (30–32). Ubiquitination
of these lysine residues is required for NF-κB activation in T
cells and pro-survival signaling in ABC DLBCL cells (31–33).
Deficiency in HOIP/RNF31, the catalytic subunit of LUBAC,
suppresses NF-κB signaling in Jurkat T cells whereas HOIP
activating mutations enhance NF-κB-dependent pro-survival in
ABC DLBCL cells, supporting that M1-linked ubiquitin chains
on BCL10 are enhancing CBM complex signaling (32, 34).
However, at the same time BCL10 is degraded by lysosomal or
proteasomal pathways and these processes are controlled by at
least partially overlapping ubiquitination sites (31, 35–37). In
addition, K48-linked poly-ubiquitination of CARD11 induces its
degradation (38). Thus, the BCL10-CARD11 fusion protein is
most likely strongly affected by regulatory ubiquitination and
ubiquitin conjugation in each moiety may be responsible for
activation, as well as the high turnover of the active BCL10-
CARD11 fusions. Due to the multi-layered ubiquitin regulation
and the uneven expression levels of active vs. inactive BCL10-
CARD11 fusions, this system is not an ideal tool to study the
relevance of BCL10 ubiquitination. However, it will be important
to clarify in how far BCL10 oligomerization and potential
filament formation cooperate with ubiquitination processes
to induce downstream signaling or alternatively, if BCL10
ubiquitination may also facilitate CBM complex assembly.
In BJAB B cells stable BCL10-CARD11 expression activates
MALT1 and NF-κB as strong as oncogenic variants of CARD11
derived from DLBCL tumor patients (5, 6, 25, 26), clearly
showing that the proximity of BCL10 and CARD11 alone is
sufficient to activate downstream signaling pathways. Thus, the
BCL10-CARD11 fusion already provides compelling evidence
that CARD11 acts as a seed in cells to boost lymphocyte
activation. By introducing point mutations we were also now
able to unravel the contribution of the two different CARD
interfaces. Constitutive activity of the BCL10-CARD11 fusion
no longer required the presence of an intact CARD11 CARD,
but was solely driven by the BCL10 oligomerization interface. In
contrast, stimulus-dependent MALT1 activation of the BCL10-
CARD11 fusion protein relied on an intact CARD11 CARD,
which most likely as in CARD11 WT serves as a platform
for recruitment and oligomerization of endogenous BCL10.
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Interestingly, introduction of the active oncogenic mutation
L225LI into the CARD11 coiled-coil (CC) region in the context
of the BCL10-CARD11 resulted in a fusion protein that was
hyper-active, despite the very low expression level in the BJAB
B cells. Indeed, all active BCL10-CARD11 fusion proteins
were expressed at a lower level compared to their inactive
counterparts. However, the very low expression of the hyper-
active fusion constructs indicates that there is a strong counter-
selection against the expression of these constitutively active
variants in T and B cells. Since all fusions constitutively activate
theMALT1 paracaspase in the two cell types, it is possible that the
sustainedMALT1 cleavage of mRNA processing factors Regnase-
1 and Roquin1/2 may exert toxic effects that impair T and B
cell survival (39, 40). More work is needed to understand under
which circumstances chronic activation induces cell survival or
toxicity.
While expression of BCL10-CARD11 fusion drives NF-
κB activation in BJAB B cells, constitutive and inducible
NF-κB signaling is severely impaired in Jurkat T cells
expressing the fusion protein. Even though NF-κB activation
is impaired in Jurkat T cells, MALT1 protease is still
strongly activated by BCL10-CARD11 fusions, demonstrating
that not all CBM downstream effects are affected. Further,
the reduced responsiveness relies on the stable expression
of the BCL10-CARD11 fusion protein and it needs to be
explored what cell-intrinsic mechanisms operate in Jurkat T
cells that counteract constitutive activation of the canonical
NF-κB pathway downstream of the CBM complex. Of note, T
lymphocytes from patients with germline activating CARD11
mutations are anergic, while the B cells are activated and
expanding, causing a phenotype called BENTA (B cell expansion
with NF-κB and T cell anergy) (41, 42). It will be interesting to
see whether similar negative regulatory mechanisms observed in
Jurkat T cells driven by an active BCL10-CARD11 fusion could
also operate in primary T cells.
Our data suggest that upon the initial BCL10 recruitment to
CARD11, the weak heterotypic interaction of the monomeric
CARDs needs to be stabilized by further interactions arising from
the oligomerized CARD11 seed and the helical BCL10 filaments.
The additional contact points within this multimeric complex are
essential for a high affinity binding and the formation of a stable
CBM complex that is competent to trigger downstream signaling.
Furthermore, the structural rigidity in the core BCL10-MALT1
filament may stabilize the binding, which is in line with the
observation that CARD11 binding is also reduced when BCL10 is
not complexed with MALT1 (14). In conclusion, we demonstrate
that the recruitment of BCL10-MALT1 to CARD11 and BCL10-
MALT1 filament formation are highly interconnected processes
that cooperate to drive CBM downstream effects in response to
physiological or pathological activation of T and B cells.
MATERIALS AND METHODS
Cell Lines and Treatments
Cell lines were maintained at 37◦C in a humidified atmosphere at
5% CO2. Jurkat T cells and BJAB B cells were cultured in RPMI
1640 Medium, and U2OS and HEK293T cells in DMEM. Media
were supplemented with 10% (Jurkat T cells, U2OS, HEK293T)
or 15% (BJAB B cells) fetal calf serum, 100 U/ml penicillin
and 100µg/ml streptomycin. U2OS, HEK293T and BJAB B cells
were obtained from the DSMZ, Jurkat T cells were authenticated
by the Authentication Service of the Leibniz Institute DSMZ.
Jurkat T cells were stimulated with Phorbol 12-Myristate 13-
Acetate (PMA: 200 ng/ml; Merck) and Ionomycin (300 ng/ml;
Calbiochem) for 30min, except if otherwise stated.
DNA Constructs and Antibodies
DNA constructs and antibodies used in this study are listed in
Tables 1, 2, respectively.
Generation and Reconstitution of
Knock-Out Cells
Bicistronic expression vector px458 expressing Cas9 and sgRNA
(45, 46) was digested with BbsI and the linearized vector
TABLE 1 | DNA constructs.
pHAGE-1CD2-T2A Lentiviral transfer vector used (43)
pMD2.G Lentiviral packaging construct (Addgene: Plasmid
#12259)
psPAX2 Lentiviral packaging construct (Addgene: Plasmid
#12260)
pHAGE-1CD2-T2A-SF Lentiviral transfer vector (mock)
CARD11-FS constructs CARD11, CARD11 R35A, and CARD11 L225LI in
pHAGE-1CD2-T2A (25)
BCL10-FS constructs BCL10 and BCL10 R42E in pHAGE-1CD2-T2A
SF-BCL10-CARD11
(B10-C11) constructs
CARD11 and CARD11 mutants (R35A,
R35A/L225LI) in SF-BCL10, SF-BCL10 R42E,
SF-BCL10 R228A, or SF-BCL10 R42E/R228A
containing pHAGE-1CD2-T2A
pGL3-6xNF-κB luc NF-κB reporter firefly luciferase (44)
pRL-TKluc TK reporter renilla luciferase (Promega)
TABLE 2 | Antibodies.
Primary antibodies Source
A20/TNFAIP3 (D13H3) Cell Signaling
BCL10 (C-17) Santa Cruz
BCL10 (H-197) Santa Cruz
CARMA1/CARD11 (1D12) Cell Signaling
CYLD (E-10) Santa Cruz
HOIL-1 (S150D) MRC
IκBα (L35A5) Cell Signaling
IκBα (phospho-Ser32/36) (5A5) Cell Signaling
MALT1 (B-12) Santa Cruz
StrepTagII IBA
β-Actin (I-19) Santa Cruz
anti-CD2-APC (RPA-2.10) eBioscience
Secondary antibodies Source
HRP-conjugated anti-goat Jackson ImmunoResearch
HRP-conjugated anti-mouse Jackson ImmunoResearch
HRP-conjugated anti-rabbit Jackson ImmunoResearch
HRP-conjugated anti-sheep Jackson ImmunoResearch
Alexa Fluor488-donkey anti-mouse Invitrogen
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was gel purified. Targeting oligos (CARD11: 5′CTCATCA
ATGACCTTACACTGACGCAGGTAGG 3′BCL10: 5′AGT
GAGGTCCTCCTCGGTGA 3′and 5′TTCCGCTTTCGTCTC
CCGCT 3′) for each targeting site positioned as depicted in
Supplementary Figures 2A,B, were annealed and ligated to
the linearized vector. Jurkat T cells or BJAB B cells (4–8 ×
106) were electroporated (220V and 1,000 µF) using a Gene
pulser X (Biorad) with px458 plasmids expressing sgRNA
targeting CARD11 or BCL10, as well as a EGFP expression
cassette. Twenty-four to forty-eight hours after electroporation,
GFP positive cells were sorted using a MoFlow sorting system.
Isolation of clonal cell lines was achieved by serial dilutions
and was followed by an appropriate expansion period. KO cell
clones were initially identified by detecting CARD11 or BCL10,
respectively, by Western Blot. Clones lacking protein expression
were genotyped by genomic PCR using intronic primers flanking
targeting sides.
For reconstitution, lentivirus was produced in HEK293T cells.
1 × 106 HEK293T cells were seeded in 8ml DMEM medium
(10% FCS, 1% Pen/Strep) in 10 cm2 dishes and grown overnight
at 37◦C. The next day, the cells were transfected with 1.5 µg of
the packaging vector psPAX2, 1.0 µg of the lentiviral envelope
plasmid pMD2.G and 2 µg pHAGE transfer vector using X-
tremeGENE HP DNA Transfection Reagent (Roche) according
to the manufacturer’s protocol. After 3 days the supernatant
of the HEK293T cells containing the virus was sterile filtered
(0.45µm). For transduction, virus supernatant was transferred
to 5 × 105 Jurkat T cells or BJAB B cells. For BJAB B cells,
supernatant was concentrated with Amicon centrifugal filter
units (100K) prior to transduction. The solution was filled up
with RPMI medium (10% FCS, 1% Pen/Strep) to a final volume
of 2–2.5ml and mixed with Polybrene (8µg/ml). To enhance
transduction efficiency, BJABs were centrifuged for 1 h at 500
× g. Forty to seventy-two hours later, cells were washed with
PBS (without calcium and magnesium) and re-suspended in 1–
2ml RPMI medium (10% FCS, 1% Pen/Strep). Seven to ten days
after transduction infection was analyzed by determining 1CD2
surface expression by FACS and CARD11 or BCL10 protein
expression by Western Blot. Only cells yielding a transduction
efficiency of >90% as determined by FACS analysis, were used
for further analyses.
Generation and reconstitution of MALT1-deficient Jurkat T
cells has been described (22).
Flow Cytometry (FACS)
Surface expression of1CD2 after lentiviral transduction of BJAB
B cells or Jurkat T cells was assessed by incubating 200 µl of the
cell culture for 15min at room temperature with 2 µl anti-CD2-
APC (RPA-2.10) antibody. Cells were centrifuged (1,100 rpm,
5min) and re-suspended in 250µl PBS before FACS using Attune
Acoustic Focusing Flow Cytometer.
Cell Lysis and Precipitations
For analysis of expression via Western Blot or EMSA, cells (1–
3 × 106) were harvested (300 × g, 5min, 4◦C) and washed
once with ice cold PBS. The pellet was resuspended in 80–100
µl high salt buffer (20mM HEPES pH 7.9, 350mM NaCl, 20%
glycerol, 1mMMgCl2, 0.5mM EDTA, 0.1mMEGTA, 1%NP-40,
1mM DTT, 10mM sodium fluoride, 8mM β-glycerophosphate,
300µM sodium vanadate and Roche protease inhibitor cocktail).
For binding studies, cells (1–5 × 107) were lysed in co-IP buffer
(25mMHEPES pH 7.5, 150mMNaCl, 0.2%NP-40, 10% glycerol,
1mM DTT, 10mM sodium fluoride, 8mM β-glycerophosphate,
300µM sodium vanadate and protease inhibitor cocktail). Lysate
controls were mixed with 4xSDS loading dye and boiled.
For StrepTactin pull-downs (ST-PD), 20–40 µl Strep-Tactin
Sepharose (1:1 suspension) was used for binding of Strep-tagged
BCL10 or BCL10-CARD11 fusion overnight at 4◦C rotating.
Sepharose beads were pelleted after incubation (100 × g, 4min,
4◦C), washed 3x with co-IP buffer, and boiled after the addition
of 20 µl 2xSDS loading dye (Roti-load). Lysates and ST-PDs were
separated by SDS-PAGE and analyzed by Western Blot.
Western Blot
Proteins were transferred onto PVDF-membranes for
immunodetection using an electrophoretic semi-dry transfer
system. After transfer, membranes were blocked with 5% BSA
for 1 h at RT and incubated with specific primary antibodies
(indicated above, diluted 1:1,000 in 2.5% BSA/PBS-T) overnight
at 4◦C. Membranes were washed in PBS-T before the addition of
HRP-coupled secondary antibodies (indicated above, 1:7,000 in
1.25% BSA in PBS-T; 1 h, RT). HRP was detected by enhanced
chemiluminescence (ECL) using the LumiGlo reagent (Cell
Signaling) according to manufacturer’s instructions.
Electrophoretic Mobility Shift Assay
(EMSA)
For EMSAs, double-stranded NF-κB (H2K: fw: 5′-GATCCA
GGGCTGGGGATTCCCCATCTCCACAGG-3′, rev: 5′- GAT
CCCTGTGGAGATGGGGAATCCCCAGCCCTG-3′), and
OCT1 binding sequences (fw: 5′- GATCTGTCGAATGCA
AATCACTAGAA-3′, rev: 5′-GATCTTCTAGTGATTTGCATT
CGACA-3′) were labeled with [α-32P] dATP using Klenow
Fragment (NEB). To monitor DNA binding, whole cell lysates
(3–6 µg) were incubated for 30min at RT with shift-buffer
[20mM HEPES pH 7.9, 120mM KCl, 4% Ficoll, 5mM DTT, 10
µg BSA and 2 µg poly-dI-dC (Roche)] and radioactive double
stranded NF-κB or OCT1 probes (10,000–20,000 cpm). Samples
were separated on a 5% polyacrylamide gel in TBE buffer,
vacuum-dried and exposed to autoradiography.
Confocal Immunofluorescence Microscopy
The localization and distribution of BCL10 was analyzed by
seeding U2OS cells in 96-well plates. Cells were transfected
using Lipofectamine 3000 Transfection Reagent (Invitrogene)
according to the manufacturer’s instructions. To optimize cell
attachment, CellCarrier-96 black plates (PerkinElmer) were
coated with 100 µl poly-D-lysine at a concentration of 50µg/ml.
Twenty-four hours after transfection, cells were washed with
PBS and fixed with 60 µl Methanol (−20◦C) for 5–10min
at room temperature and then washed 3x with PBS. For
immunostaining, cells were blocked in 2% BSA in PBS. Cells
were incubated with primary antibody (anti-StrepTagII) in
blocking buffer for 2 h at RT. Cells were washed 3x for
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10min at RT, before incubation with secondary antibody (Alexa
Fluor488-donkey anti-mouse) in blocking buffer for 1 h at
RT. Cell nuclei were visualized by incubation with Hoechst
33342 dye (Life Technologies) in PBS at a concentration
of 0.5µg/ml for 30min at RT. Afterwards the cells were
washed and covered with PBS, sealed with foil and kept
at 4◦C in the dark until microscopy. Confocal microscopy
was performed with an Operetta high-content imaging system
(Perkin-Elmer).
Labeling and Biotin Pull-Down (PD) of
Active MALT1
The biotin-labeled MALT1 activity based probe (MALT1-ABP)
has been described previously (19). To investigate MALT1
protease activity, Jurkat T cells (3 x 107) were washed with PBS,
and lysed in 600 µl co-IP buffer without protease inhibitors
for 30min at 4◦C. After clearing the lysates by centrifugation
(20,000 × g, 4◦C, 15min), 30 µl were collected as lysate control,
mixed with 4x SDS loading buffer and boiled for 5min at 95◦C.
To 550 µl of the supernatant 12 µl High Capacity Streptavidin
Beads (Thermo Fisher) was added and incubated for 1 h at 4◦C
for pre-clearing. The beads were pelleted (4,000 rpm, 2min,
4◦C) and 450 µl of supernatant was mixed with MALT1-ABP
probe (0.1µM final concentration). After 1 h rotating at room
temperature, 15 µl High Capacity Streptavidin Beads was added
before 1–2 h incubation at 4◦C (rotating). Beads were collected
and washed 3x with co-IP buffer without protease inhibitors.
Beads were re-suspended in 22 µl 2x SDS loading buffer and
boiled at 95◦C for 7min before SDS-PAGE and Western Blot
analysis.
NF-κB Reporter Assay
For NF-κB luciferase reporter assays, 8 × 106 Jurkat cells were
transfected by electroporation with 2 µg NF-κB firefly luciferase
reporter plasmid, 1 µg renilla luciferase and 6 µg of CARD11
and BCL10-CARD11 fusion constructs using 220V and 1,000
µF (Gene Pulser X, BioRad). After cultivation for 72 h cells were
lysed in passive lysis buffer and luciferase activity measured using
a dual luciferase reporter kit according to the manufacturer’s
protocol (Promega). All luciferase values were calculated in
relation to the Renilla control.
Quantitative Reverse-Transcriptase
Polymerase Chain Reaction (qRT-PCR)
RNA was isolated (QIAGEN RNeasy Kit) and equal amounts
of RNA (InviTrap Spin Universal RNA Mini Kit, 1060100200,
Stratec) were transcribed into cDNA using the Verso cDNA
synthesis Kit (AB1453B, Thermo Fisher Scientific). Quantitative
real-time (qRT) PCR was performed using KAPA SYBR FAST
qPCR Master Mix (KAPA Biosystems) and standard LightCycler
protocol on a Roche LightCycler 480. RNA Polymerase II (PolII)
served as internal standard. The following primers were used: fw:
5′-CCGCACCTCCACTCCATCC-3′ rev: 5′-ACATCAGCACCC
AAGGACACC-3′; RPII fw: 5′-GCACCACGTCCAATGACA-3′
rev: 5′-GTGCGGCTGCTTCCATAA-3′. Results represent the
mean and standard error of the mean of three independent
experiments.
Structural Model of CARD11-BCL10 and
BCL10-BCL10 Interaction Surfaces
The CARD11-BCL10 CARD/CARD interaction model
was prepared under consideration of the surface charge
complementarity analysis of the BCL10-MALT1 filament
cryo EM structure (EMD-0013, PDB 6GK2) and the
crystal structure of the CARD11 domain (PDB 4LWD)
(Supplementary Figure 1). The CARD11 CARD structure
has been superimposed on the BCL10 CARD within
the BCL10-MALT1 filament using the align command
in PyMOL (The PyMOL Molecular Graphics System,
Version 2.0 Schrödinger, LLC). Under consideration that
the mutation of residue R35 in CARD11 abolishes the
interaction to BCL10 (12), we propose that the mainly
positively charged top of the CARD11 CARD interacts
with the negatively charged bottom of the Bcl10 filament
(Supplementary Figures 1B,C). The electrostatic surface was
calculated with the program APBS Tool 2.1 implemented in
PyMOL (47).
Statistical Analysis
Data for luciferase reporter assay, quantitative RT-PCR
and fluorescence microscopy was analyzed for statistical
significance using the unpaired Student’s t-test (∗∗p
≤ 0.01, ∗∗∗p ≤ 0.001). Sample size (n) is specified
for each experiment and data are shown as mean ±
s.e.m.
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